<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>临床试验招募信息 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-11T11:14:04+08:00</updated>
  <subtitle>帮您更方便、更快捷的了解正在开展的临床试验招募信息！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【招募患者】评价在晚期实体瘤中给予Lurbinectedin的安全性、PK特征及有效性的单臂、开放、剂量递增及扩展的I期临床研究</title>
    <updated>2020-11-11T08:17:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-11:/s/996Wu0nU9mCkqsCZmnboZg</id>
    <link href="https://mp.weixin.qq.com/s/996Wu0nU9mCkqsCZmnboZg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【普瑞金CAR-T招募1】靶向BCMA的嵌合抗原受体T细胞注射液在BCMA阳性的复发/难治多发性骨髓瘤的I期临床研究</title>
    <updated>2020-11-10T09:11:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-10:/s/TsECEZIJbyzKeiozsubNlQ</id>
    <link href="https://mp.weixin.qq.com/s/TsECEZIJbyzKeiozsubNlQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【宝船PD-L1招募患者2】全人源抗PD-L1抗体治疗泌尿及男性生殖系统肿瘤有效性和安全性的、单臂、开放、多中心、II期临床研究</title>
    <updated>2020-11-09T08:06:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-09:/s/ZYNlpPHPSn4FpJnkDVNX7w</id>
    <link href="https://mp.weixin.qq.com/s/ZYNlpPHPSn4FpJnkDVNX7w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评价AST-3424 治疗复发难治性急淋白血病的安全性、PK、初步疗效以及疗效与AKR1C3 酶表达相关性的临床研究</title>
    <updated>2020-11-08T07:31:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-08:/s/53v0ajd7by5cyAnl0sj06g</id>
    <link href="https://mp.weixin.qq.com/s/53v0ajd7by5cyAnl0sj06g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】在EGFR阳性晚期非小细胞肺癌患者中评估MRG003有效性和安全性的II期研究</title>
    <updated>2020-11-06T07:49:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/jLieSZIBcpilBm4lRrnD_w</id>
    <link href="https://mp.weixin.qq.com/s/jLieSZIBcpilBm4lRrnD_w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【默沙东PD-1招募29】帕博利珠单抗联合同步放化疗序贯帕博利珠单抗联合奥拉帕利用于治疗III期NSCLC的III期研究</title>
    <updated>2020-11-05T14:12:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/JYwBcHgSxAQGXxXQRrfOYg</id>
    <link href="https://mp.weixin.qq.com/s/JYwBcHgSxAQGXxXQRrfOYg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】吉马替康（ST 1481）二线治疗局部晚期或转移性胰腺癌患者有效性和安全性的随机、对照、开放的Ⅱ期临床研究</title>
    <updated>2020-11-04T07:50:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/fNdZuvS5j30mAStbLFtN1A</id>
    <link href="https://mp.weixin.qq.com/s/fNdZuvS5j30mAStbLFtN1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【厚德奥科PD-L1招募患者6】LP002治疗复发或难治性原发纵隔大B细胞淋巴瘤患者的多中心、开放性、单臂Ⅱ期研究</title>
    <updated>2020-11-03T07:43:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/_efwvr7e8zOr8B1VS2Y3eA</id>
    <link href="https://mp.weixin.qq.com/s/_efwvr7e8zOr8B1VS2Y3eA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】评估AK112用于治疗晚期实体瘤的安全性、药代动力学和抗肿瘤活性的开放、多中心、剂量递增和剂量扩展I/II期临床试验</title>
    <updated>2020-11-02T07:41:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/4-7Qx2uFZXkqWINtFkAUsA</id>
    <link href="https://mp.weixin.qq.com/s/4-7Qx2uFZXkqWINtFkAUsA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【正大天晴PD-L1招募患者19】TQB2450注射液治疗PD-L1阳性的复发或转移性宫颈癌的单臂、开放、多中心II期临床试验</title>
    <updated>2020-11-01T08:44:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-01:/s/WlPdbMRKKJ2RFoYR8nhB9w</id>
    <link href="https://mp.weixin.qq.com/s/WlPdbMRKKJ2RFoYR8nhB9w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>